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Purpose: We evaluated the effectiveness of second-line maximum androgen blockade 
(MAB) with an alternative antiandrogen in patients who relapsed after initial MAB.
Materials and Methods: We retrospectively analyzed 47 patients with prostate cancer 
who relapsed after initial MAB, including surgical or medical castration combined with 
antiandrogens, from January 1998 to December 2009. When the serum prostate-specif-
ic antigen (PSA) level was increased on three consecutive occasions, we discontinued 
the antiandrogen and then administered an alternative antiandrogen. Seven patients 
were assessed for antiandrogen withdrawal syndrome (AWS). The effect of the sec-
ond-line MAB was evaluated by the serum PSA level, and response was subdivided into 
≥50% and ＜50% PSA reductions from the baseline PSA at the start of second-line 
MAB. 
Results: PSA reduction was observed in 32 patients (68.1%). Among them, 23 (48.9%) 
achieved ≥50% PSA reductions with a mean response duration of 13.4±5.4 months. 
Nine (19.2%) patients reached ＜50% PSA reductions with a mean response duration 
of 12.2±6.2 months. The time to nadir PSA level after first-line MAB in the ≥50% PSA 
reduction group, ＜50% PSA reduction group, and PSA elevation group was 15.6±12.9
months, 11.8±6.0 months, and 8±6.5 months, respectively. That is to say, it was sig-
nificantly longer in the responder groups (p=0.038).
Conclusions: Second-line MAB using an alternative antiandrogen is an effective treat-
ment option before cytotoxic chemotherapy in patients who relapse after initial MAB.
Key Words: Androgen antagonists; Prostate-specific antigen; Prostatic neoplasms
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 4 May, 2011
accepted 20 June, 2011
Corresponding Author:
Tae Young Jung
Department of Urology, Seoul Veterans 
Hospital, 6-2, Dunchon 2-dong, 
Gangdong-gu, Seoul 134-791, Korea
TEL: +82-2-2225-1739
FAX: +82-2-484-4604
E-mail: urodoct@hotmail.com
INTRODUCTION
Almost all prostate cancers express androgen receptor, and 
the growth and survival of prostate cancer initially de-
pends on continued activation of the androgen receptor by 
androgens. Therefore, androgen deprivation therapy 
(ADT) has been a mainstay of treatment against prostate 
cancer [1,2]. The use of ADT has been increasing steadily 
in all stages of prostate cancer: as primary therapy for those 
with localized disease or who are unfit for radical local 
treatment, as an adjunct to radiotherapy or surgery for 
those with locally advanced (high-risk) disease, as treat-
ment for biochemical relapse after failure of localized ther-
apy, and as treatment for men with metastatic disease, 
with and without symptoms [2,3].
　Although the majority of patients with prostate cancer 
initially respond to ADT, almost all patients ultimately de-
velop tumor progression despite castrate levels of testos-
terone, which is often referred to as castration-resistant 
prostate cancer (CRPC) [4-7]. Treatment options for CRPC 
remain limited, and the prognosis of patients with CRPC 
is dismal, with a median survival of 12 to 18 months [5]. 
For management of these patients, antiandrogen with-
drawal, second-line ADT (alternative antiandrogen, estro-
gen and ketoconazole), and cytotoxic chemotherapy may be 
considered [2,8].
　Despite advances in cytotoxic chemotherapy, second- 
line ADT is often used after the development of CRPC be-Korean J Urol 2011;52:461-465
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TABLE 1. Patient characteristics
No. of patients      47
Mean age±SD (yr)   75.9±6.5
Initial PSA (ng/ml)
    Mean±SD 227.7±602.6
    Range   4.49-3,497
No. Gleason score (%)
a
    ≤6     7 (15.2)
    7   12 (26.1)
    8-10   27 (58.7)
No. T category (%)
    T2   19 (40.4)
    T3   21 (44.7)
    T4     7 (14.9)
No. N category (%)
    N0   31 (66.0)
    N＋   16 (34.0)
No. M category (%)
    M0   34 (72.3)
    M＋   13 (27.7)
No. castration (%)
    LHRH agonist   38 (80.9)
    Orchiectomy     9 (19.1) 
No. assessed AWS 
    Yes (response/no response)     7 (3/4)
    No      40
AWS: antiandrogen withdrawal syndrome, LHRH: luteinizing 
hormone-releasing hormone, PSA: prostate-specific antigen, 
a: a
Gleason score could not be determined in one patient with muci-
nous prostate adenocarcinoma.
cause many patients with CRPC remain sensitive to secon-
dary hormonal manipulations. Second-line ADT either 
lowers the androgen levels further or directly antagonizes 
the androgen receptor in prostate cancer cells [1,7]. Several 
investigators have reported the usefulness of alternative 
ADT for treating resistance to first-line ADT [1,9-15].
　Therefore, we analyzed the clinical effects of an alter-
native antiandrogen for second-line maximum androgen 
blockade (MAB) in patients with relapsing prostate cancer 
who received first-line MAB in Korea.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 47 pa-
tients with histologically confirmed prostate cancer who 
relapsed after initial MAB from January 1998 to December 
2009. 
　For first-line therapy, all patients were initially treated 
with MAB consisting of either bilateral orchiectomy or 
medical castration with luteinizing hormone-releasing 
hormone (LHRH) agonist (3.6 mg goserelin acetate or 3.75 
mg leuprorelin acetate every 4 weeks) plus antiandrogen 
(50 mg bicalutamide or 200 mg cyproterone acetate daily). 
The selection of the antiandrogen drug was left to the in-
dividual doctor’s discretion.
　Serum prostate-specific antigen (PSA) levels were meas-
ured by using a chemiluminescent enzyme immunoassay 
at least once every 4 or 8 weeks. Clinical staging was eval-
uated according to the 1997 TNM classification.
　If disease was determined to be relapsed (increasing PSA 
on 3 successive occasions) after initial MAB, the first-line 
antiandrogen was stopped. In 7 patients, the patients were 
assessed for antiandrogen withdrawal syndrome (AWS) 
and an alternative antiandrogen (switching from bicaluta-
mide to cyproterone acetate or from cyproterone acetate to 
bicalutamide) was then started. In 40 patients, second-line 
MAB therapy with an alternative antiandrogen was start-
ed without evaluation of AWS. AWS was defined as a de-
crease in PSA levels of greater than 50% after the stoppage 
of initial antiandrogen. In all cases, LHRH agonist admin-
istration was continued to maintain medical castration af-
ter failure of first-line MAB.
　We investigated age, initial serum PSA level, Gleason 
score, clinical stage, and AWS response. We also analyzed 
serum PSA level (baseline and nadir), response to ADT, 
time to nadir PSA, and response duration for both first- and 
second-line MAB. 
　With first-line MAB, a complete response (CR) was de-
fined as a decrease in PSA levels to less than 4 ng/ml, where-
as a partial response (PR) was considered to be a decrease 
in PSA levels of greater than 50% with a concentration not 
less than 4 ng/ml.
　For all patients in this study, the duration of response 
was defined as the period from the start of ADT to increas-
ing PSA on 3 consecutive occasions. 
　We classified the patients as responders (subdivided into 
2 groups: ≥50% and ＜50% PSA reductions) and non-
responders (PSA elevation) in second-line MAB. We then 
compared these 3 groups with respect to the above-men-
tioned factors to clarify the clinical differences.
　The method of statistical analysis used was ANOVA and 
chi-square test (with Fisher’s exact test) using SPSS ver. 
15.0 (SPSS Inc., Chicago, IL, USA). A p-value of ＜0.05 was 
considered to be statistically significant.
RESULTS
Patient characteristics are presented in Table 1. The age 
distribution ranged from 62 to 87 years with a mean age 
of 75.9±6.5 years. PSA before treatment was 227.7±602.6 
ng/ml (range, 4.49-3,497 ng/ml). Gleason scores were less 
than 7 in 7 patients (15.2%), 7 in 12 patients (26.1%), and 
more than 8 in 27 patients (58.7%). We could not determine 
the Gleason score in one patient with mucinous prostate 
adenocarcinoma. For clinical stage, greater than T3 dis-
ease, regional lymph node metastases, and distant meta-
stases were found in 28 (59.6%) patients, 16 (34.0%) pa-
tients, and 13 (27.7%) patients, respectively. In first-line 
MAB, orchiectomy was performed in 9 patients (19.1%) and 
LHRH agonists were administered in 38 patients (80.9%). 
AWS was assessed in 7 patients and observed in 3 (42.9%) 
patients with a mean duration of 2.7 months.
　Clinical factors in responders and nonresponders to sec-Korean J Urol 2011;52:461-465
Efficacy of Alternative Antiandrogen Therapy 463
TABLE 2. Comparisons of clinical factors in responders and nonresponders to second-line MAB
50% or greater 0 to 49% None p-value
No. of patients       23       9       15
Mean age±SD       75.3     75.4       77.2 0.655
a
Mean initial PSA at first-line MAB±SD (ng/ml) 122.6±212.1 64.8±28.1 486.8±1,007.4 0.157
a
No. Gleason score (%)
c 0.471
b
    ≤6         4       2         1
    7         5       3         4
    8-10       14       4         9
No. T stage (%) 0.319
b
    T2       12       4         3
    T3       11       5         9
    T4         0       0         3
No. N stage (%) 0.540
b
    N0       16       7         8
    N1         7       2         7
No. M stage (%) 0.283
b
    M0       17       8         9
    M1         6       1         6
No. response to first-line MAB 0.114
b
    CR       16       9         9
    PR         5       0         6
    No response         2       0         0
Mean nadir PSA±SD after first-line MAB (ng/ml)   31.6±135.7   0.5±0.6   14.8±46.8 0.538
a
Mean time±SD to nadir PSA after first-line MAB (month)    15.6±12.9 11.8±6.0        8±6.5 0.038
a
Mean±SD response duration of first-line MAB (months)   23.5±13.7 30.2±19.6   16.8±11.5 0.149
a
No. AWS 0.657
b
    Yes         3       2         2
    No       20       7       13
No. AWS response
    Yes         2       1         0
    No         1       1         2
Mean starting PSA at second-line MAB±SD (ng/ml)   95.2±259.7 21.8±37.2   55.8±102.1 0.416
a
Mean nadir PSA±SD after second-line MAB (ng/ml)   23.6±67.9 16.5±28.6   89.5±146.6 0.093
a
Mean time±SD to nadir PSA after second-line MAB (month)      6.6±5.6   4.3±4.0        0±0 ＜0.003
a
Mean±SD response duration of second-line MAB (months)   13.4±5.4 12.2±6.2        0±0 ＜0.003
a
AWS: antiandrogen withdrawal syndrome, CR: complete response, MAB: maximum androgen blockade, PR: partial response, PSA:
prostate-specific antigen, 
a: ANOVA, 
b: chi-square test (with Fisher’s exact test), 
c: a Gleason score could not be determined in one patient
with mucinous prostate adenocarcinoma.
ond-line MAB are compared in Table 2. Of the 47 patients 
treated with second-line MAB, 32 (68.1%) were considered 
to be responders. Twenty-three (48.9%) achieved ≥50% 
PSA reductions (mean response duration: 13.4±5.4 mon-
ths) and 9 (19.2%) reached ＜50% PSA reductions (mean 
response duration: 12.2±6.2 months). Fifteen (31.9%) of 
the 47 patients had an increase in the PSA level with sec-
ond-line MAB and were considered to be nonresponders.
　There were no statistically significant differences be-
tween these groups except that the time to nadir PSA level 
after first-line MAB of the second-line responders was lon-
ger than that of the nonresponders (p=0.038). The time to 
nadir PSA level after first-line MAB was 15.6±12.9 
months, 11.8±6.0 months, and 8±6.5 months in the ≥50% 
PSA reduction group, ＜50% PSA reduction group, and 
PSA elevation group, respectively.
DISCUSSION
Prostate cancer is the most common cancer in men in the 
United States and the incidence of this disease is rapidly 
increasing in Korea [5,16]. Traditionally, androgen depri-
vation was achieved by bilateral orchiectomy and oral es-
trogen [17]. The goal with ADT is to reach castrate levels 
of testosterone. From this point of view, elimination of the 
production of gonadal testosterone can be insufficient be-
cause a small amount of testosterone is produced in the 
adrenal glands and contributes to prostate cancer pro-
gression. Huggins and Scott demonstrated the secondary 
benefit of a bilateral adrenalectomy in a castrated man 
[18]. Their finding of a clinical benefit from eliminating all 
androgens produced in the body was the first demon-
stration of the benefit of MAB [4]. MAB has progressed with 
the discovery of LHRHs, the development of LHRH ago-
nists, and the discovery of antiandrogens [4]. From the Korean J Urol 2011;52:461-465
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most recent systematic reviews and meta-analyses, it ap-
pears that at a follow-up of 5 years, MAB with anti-
androgens provides a small but statistically significant 
survival advantage (＜5%) when compared with LHRH 
monotherapy [6,19,20].
　Initially, ADT is effective against prostate cancer. But 
nearly all patients develop tumor progression despite cas-
trate levels of testosterone [4-8,21]. This clinical condition 
has been described as androgen-independent or hor-
mone-refractory prostate cancer (HRPC). However, these 
previously used terms have largely been replaced with the 
term CRPC, with the awareness of the persistent androgen 
receptor signaling activity despite castrate serum testos-
terone levels [5]. It is important to differentiate CRPC from 
true HRPC. Although CRPC responds to secondary hormo-
nal manipulations, true HRPC resists all hormonal meas-
ures [6].
　No clear-cut recommendation can be made for patients 
with PSA elevation after first-line MAB. In the 2010 ver-
sion of the European Association of Urology (EAU) guide-
lines, it is recommended to continue ADT with LHRH ago-
nists, despite PSA progression; to stop antiandrogen ther-
apy once PSA progression is documented after first-line 
MAB; and then to assess AWS [6]. AWS was initially docu-
mented in patients who discontinued flutamide upon the 
development of CRPC [6,22]. In many previous studies, re-
sponse was observed within 2 to 6 weeks after anti-
androgen withdrawal and ≥50% PSA reduction was ach-
ieved in 15% to 30% of patients. But the response duration 
is short, with a median duration of 3.5 to 5 months 
[6,10,11,14,22,23]. In the present study, 7 of 47 patients 
were evaluated for AWS. AWS was observed in 3 of 7 
(42.9%) patients with a mean response duration of 2.7 
months. Because there is no standard treatment for pa-
tients with disease progression after first-line MAB, not all 
of those enrolled but only a small number of patients were 
assessed for AWS. Therefore, our results are not consistent 
with the analysis of previous reports related to AWS.
　Based on prospective randomized phase 3 trials, doce-
taxel at 75 mg/m
2 at 3-wk intervals in combination with 
prednisone represents the cytotoxic regimen of choice in 
men with CRPC resulting in a median survival benefit of 
3 months and a significant improvement of pain and qual-
ity of life when compared with mitoxantrone [6,24,25]. But 
most cytotoxic chemotherapy produces severe systemic 
side effects and reduces quality of life. Therefore, the anti-
androgen may be switched to an alternative antiandrogen 
in patients who relapse after initial MAB.
　The effectiveness of alternative antiandrogens has been 
demonstrated through various studies [1,9-15]. Miyake et 
al reported that second-line ADT (flutamide) resulted in a 
reduction of the PSA level in 25 of 55 patients (45%), the 
median (range) duration of the PSA response was 6 (1-13) 
months after the start of second-line therapy [13]. In the 
study by Suzuki et al, after switching to an alternative anti-
androgen (from bicalutamide to flutamide and from fluta-
mide to bicalutamide), ≥50% and ＜50% PSA reductions 
were observed in 35.8% and 25.4% of patients, respectively, 
and the overall response duration was more than 202 days 
[11]. Nakabayashi et al also reported that nilutamide ap-
peared to have activity as a secondary ADT, and 8 of 45 pa-
tients (40%) achieved ≥50% PSA reductions with a median 
(range) time to progression of 4.4 (range, 0.31-44.7) months 
[14]. In the present study, after second-line MAB, there was 
a PSA reduction in 32 of the 47 (68.1%) patients and 23 of 
the 47 (48.9%) patients achieved ≥50% PSA reduction. The 
mean duration of PSA response was 13.4±5.4 months in the 
≥50% PSA reduction group and 12.2±6.2 months in the 
＜50% PSA reduction group. The mean duration of PSA re-
sponse in our studies was longer than in previous reports. 
This result may be because of the relatively small study 
population (sample size) with three patients showing a 
very long response duration (21, 25, and 29 months) and 
early switching to an alternative antiandrogen by frequent 
PSA follow-up.
　In view of the clinical characteristics of responders to sec-
ond-line MAB, various predictive factors have been sug-
gested through previous studies. Suzuki et al reported that 
the significant clinical factors that predicted the response 
to second-line ADT were clinical stage, M category, and the 
response to first-line MAB therapy [11]. Nishimura et al 
concluded that patients who had a longer response dura-
tion to first-line MAB had a significantly greater response 
to second-line MAB [12]. Miyake et al reported that pa-
tients without bone metastases or those whose disease pro-
gressed ＞1 year after first-line therapy had a significantly 
higher incidence of PSA response to second-line therapy 
[13]. Compared with previous studies, our study showed 
that the significant clinical factor predicting response to 
second-line MAB was the time to nadir PSA level after 
first-line MAB.
　This study had several limitations. First, our study was 
retrospective and had a relatively small study population. 
Furthermore, only 7 of 47 patients (14.9%) were assessed 
for AWS. For these reasons, the mean response duration 
of second-line MAB and the predictive factors of good re-
sponsiveness to second-line MAB differed from previous 
studies. Second, we could not evaluate patient survival, 
such as cause-specific survival and overall survival. Large, 
prospective, randomized clinical trials including the anal-
ysis of survival benefit of alternative antiandrogen therapy 
should be conducted.
CONCLUSIONS
Our results demonstrate PSA reduction in 68.1% of pa-
tients who relapse after initial MAB, with a response dura-
tion of 13 months, and confirm previous findings that sec-
ond-line MAB using an alternative antiandrogen is 
effective. Also, our results show that the time to nadir PSA 
level after first-line MAB predicts responsiveness to sec-
ond-line MAB.
　Second-line MAB using an alternative antiandrogen is 
an attractive therapeutic option and can be used to delay Korean J Urol 2011;52:461-465
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time to cytotoxic chemotherapy. Further investigation is 
necessary to clarify the clinical factors that predict re-
sponsiveness to second-line MAB and to assess whether al-
ternative antiandrogen therapy contributes to survival 
benefit.
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